Alvotech's stock fell 5.04% in post-market trading on Wednesday, following the release of its first-quarter financial results.
The biotechnology company reported revenue of $105.9 million for Q1 2026, a 20.3% decrease from the same period last year and significantly below analyst estimates of $140.85 million. Earnings per share were breakeven, missing expectations of 2 cents per share.
CEO Lisa Graver stated that both revenues and EBITDA were impacted by a production slowdown related to facility improvements, with a recovery expected as normal operations resume. The company maintained its full-year revenue guidance of $650-$700 million and adjusted EBITDA guidance of $180-$220 million.
Comments